STEMRIM
Stem Rim is a biotechnology company aiming to develop “regenerative medicine”.We are developing drugs based on a new mechanism of action that mobilizes stem cells present in the living body to the injured or diseased tissue without removing them out of the body and induces functional tissue regeneration.
STEMRIM
Social Links:
Industry:
Biotechnology Medical Product Research
Founded:
2006-10-30
Address:
Osaka, Osaka, Japan
Country:
Japan
Website Url:
http://www.stemrim.com
Total Employee:
51+
Status:
Active
Contact:
072-648-7152
Total Funding:
3.45 B JPY
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network Font Awesome
Similar Organizations
Atems
Atems is a regeneration therapy company that develops regenerative medicine and biomedical devices.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Sinocelltech
Sinocelltech is a biotech company that develops and manufactures recombinant proteins, monoclonal antibodies, and vaccines.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Kyogin Lease & Capital
Kyogin Lease & Capital investment in Venture Round - StemRIM
SMBC Venture Capital
SMBC Venture Capital investment in Venture Round - StemRIM
KSP
KSP investment in Venture Round - StemRIM
M3i
M3i investment in Venture Round - StemRIM
Miyako Capital
Miyako Capital investment in Venture Round - StemRIM
M3
M3 investment in Venture Round - StemRIM
DCI Partners
DCI Partners investment in Venture Round - StemRIM
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Venture Round - StemRIM
Kyogin Lease & Capital
Kyogin Lease & Capital investment in Venture Round - StemRIM
Miyako Capital
Miyako Capital investment in Venture Round - StemRIM
Official Site Inspections
http://www.stemrim.com Semrush global rank: 2.91 M Semrush visits lastest month: 5.52 K
- Host name: sv1175.wpx.ne.jp
- IP address: 210.157.78.46
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "StemRIM"
StemRIM
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, “Regeneration-Inducing Medicine ™ ”. “Regeneration-Inducing Medicine ™ ” is an innovative new class of medicine that induces …See details»
StemRIM - Crunchbase Company Profile & Funding
Organization. StemRIM . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. StemRIM is a bio company that specializes in …See details»
Corporate Information | StemRIM
Company name: StemRIM Inc. Established: October 30, 2006: Chief Executives: Masatsune Okajima (President & CEO) Number of Employees: 71 (as of January 31, 2024)See details»
Stemrim History | StemRIM
Changed our company name to StemRIM Inc. Apr. 2019: A corporate phase 2 clinical trial of Redasemtide in patients with Acute Ischemic Stroke started at Shionogi & Co., Ltd. Aug. 2019: …See details»
Stemrim - Company Profile - Tracxn
Nov 27, 2024 Stemrim develops regenerative technologies. They have developed their own technology, regeneration-inducing medicine, which provides medicine administration without …See details»
StemRIM - Funding, Financials, Valuation & Investors - Crunchbase
StemRIM is a bio company that specializes in developing regeneration-inducing medicines. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ...See details»
StemRIM (TYO: 4599) Company Profile & Overview - Stock Analysis
Sep 13, 2024 StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction …See details»
StemRIM Company Profile - Office Locations, Competitors ... - Craft
Oct 9, 2024 StemRIM has 5 employees at their 1 location and ¥2.35 b in annual revenue in FY 2023. See insights on StemRIM including office locations, competitors, revenue, financials, …See details»
StemRIM - VentureRadar
StemRIM is a biotechnology company aiming to develop a next generation of regenerative medicine, "Regeneration-inducing Medicine". ... Dansk Biotek Unknown n/a DANISH …See details»
Corporate Information | StemRIM
TEL +81-72-648-7152 . Saito Bio-Incubator 3F 7-7-15,Saito-Asagi,Ibaraki City,Osaka,Japan, 567-0085 MAPSee details»
StemRIM, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jul 15, 2023 Explore StemRIM, Inc. with its drug pipeline, therapeutic area, technology platform, 4 news, and 7 literature, Disease Domain:Nervous System Diseases, Technology …See details»
StemRIM - Contacts, Employees, Board Members, Advisors & Alumni
Organization. StemRIM . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... StemRIM has 5 current employee profiles, …See details»
StemRIM Company Profile & Data: stocks, market cap, financials, …
Jul 1, 2024 StemRIM was incorporated in 2006 and is based in Ibaraki, Japan. Top 1-year algo backtest: +265.99% $10,000 in October 2023 would now be $36,599 by following this …See details»
StemRIM - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 10, 2024 Organization. StemRIM . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 24. Monthly …See details»
StemRIM Secures European Patent for Cardio Treatment
53 minutes ago StemRIM Inc. has announced the upcoming European patent registration for Redasemtide, a promising regenerative medicine aimed at treating cardiomyopathy and …See details»
StemRIM (TSE:4599) Return on Common Equity - Investing.com
StemRIM's return on common equity for fiscal years ending July 2020 to 2024 averaged -7.8%. StemRIM's operated at median return on common equity of -5.4% from fiscal years ending …See details»
About “Regeneration-Inducing Medicine™” | StemRIM
TEL +81-72-648-7152 . Saito Bio-Incubator 3F 7-7-15,Saito-Asagi,Ibaraki City,Osaka,Japan, 567-0085 MAPSee details»
StemRIM Secures Australian Patent for Redasemtide Peptides
4 days ago StemRIM Inc. (JP:4599) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% OFF!Make …See details»
What is “Regeneration-Inducing Medicine™”? | StemRIM
Jul 7, 2015 Our “Regeneration-Inducing Medicine ™ ” is a next-generation regenerative medicine that realizes the same therapeutic effect as conventional regenerative medicine/cell …See details»
Investor Relations | StemRIM
TEL +81-72-648-7152 . Saito Bio-Incubator 3F 7-7-15,Saito-Asagi,Ibaraki City,Osaka,Japan, 567-0085 MAPSee details»